{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"PFS was defined as the time from the date of first dose until confirmed PD or death due to any cause, whichever occurred first. PD= increase of \\>=25% from lowest value in \\>=1 of following (serum M-protein \\[absolute increase \\>=0.5g/dL\\]; serum M-protein increase \\>=1g/dL \\[when lowest M-protein \\>=5g/dL\\]; urine M-protein \\[absolute increase \\>=200mg/24h\\]; participants without measurable serum \\& urine M-protein levels, difference between involved \\& uninvolved sFLC levels \\[absolute increase \\>10mg/dL\\]; in participants without measurable serum, urine M-protein levels \\& involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \\[absolute increase \\>=10%\\]; appearance of new lesion,\\>=50% increase from nadir in SPD of \\>1 lesion, or \\>=50% increase in longest diameter of previous lesion \\>1cm in short axis; \\>=50% increase in circulating plasma cells \\[\\>=200cells/μL\\] if this is the only measure of disease.","reportingStatus":"NOT_POSTED","timeFrame":"From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)","title":"Progression Free Survival (PFS) as Per IMWG Criteria by Investigator Assessment","type":"SECONDARY"}